证券代码：600129 证券简称：太极集团 公告编号：2025-074 重庆太极实业（集团）股份有限公司 关于公开挂牌出售闲置房产的进展公告 根据《上海证券交易所股票上市规则》及《公司章程》的规定， 本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。 公司于 2025 年 8 月 20 日召开了第十届董事会第三十一次会议， 审议通过了《关于公开挂牌出售闲置资产的议案》，同意公司以公开 挂牌方式出售上述资产，首次挂牌价格不低于评估值。董事会授权公 司管理层办理本次挂牌转让等相关事宜。具体内容详见公司于 2025 年 8 月 22 日在上海证券交易所网站（www.sse.com.cn）披露的《关 于公开挂牌出售闲置房产的公告》（公告编号：2025-064） 特此公告。 重庆太极实业（集团）股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、交易概述 为盘活闲置资产，提高资产运营效率，提高资产的流动性，重庆 太极实业（集团）股份有限公司（以下简称：公司）将名下位于成都 市成华区 ...

Core Viewpoint - Chongqing Taiji Industry (Group) Co., Ltd. has successfully sold idle real estate assets, which is expected to positively impact its financial performance in 2025 [1] Group 1: Asset Sale Details - The company decided to publicly transfer the property located at Chengdu Chenghua District, Construction Road No. 52, with a listing price based on an appraisal value of 39.136 million yuan [1] - The property was successfully sold through the Beijing Stock Exchange for a transaction price of 46.036 million yuan [1] - The company has received the full transfer payment and is in the process of handling the property transfer [1] Group 2: Financial Impact - The preliminary estimate indicates that the company will gain approximately 29 million yuan from this transaction, which will be included in the financial results for the year 2025 [1] - The financial and operational performance of the company is expected to benefit positively from this transaction, subject to the final audit results [1]

Investment Rating - The investment rating for the company is "Hold" with a downgrade from previous ratings [7]. Core Views - The company's performance is under pressure due to inventory digestion, with a significant decline in revenue and net profit in the first half of 2025 [2][4]. - The company is optimizing its marketing structure to enhance sales team vitality and improve internal collaboration [3]. - There is a focus on strengthening research and innovation capabilities to accelerate the commercialization of research outcomes [4]. Financial Performance Summary - In H1 2025, the company achieved revenue of 5.66 billion yuan, a year-on-year decrease of 27.6%, and a net profit attributable to shareholders of 139 million yuan, down 71.9% [1]. - The pharmaceutical segment saw a revenue drop of 44.03%, with core products experiencing significant declines [2]. - The revenue forecast for 2025-2026 has been revised down from 19.86 billion yuan to 10.44 billion yuan for 2025 and from 22.17 billion yuan to 11.03 billion yuan for 2026 [4]. Financial Data and Valuation - The company's total market capitalization is approximately 12.12 billion yuan, with a current price of 21.98 yuan per share [7]. - The projected earnings per share (EPS) for 2025 is 0.83 yuan, with a price-to-earnings (P/E) ratio of 26.43 [5]. - The company’s asset-liability ratio stands at 73.46%, indicating a relatively high level of debt [7].

Core Insights - Tai Chi Group's subsidiary Southwest Pharmaceutical has had its application for the generic version of Atomoxetine Hydrochloride Capsules accepted, with the original product set to cease supply in the Chinese market by January 2024 [1][2] - Atomoxetine, originally developed by Eli Lilly, is a non-stimulant medication recommended for treating ADHD in children and adolescents, with significant sales growth in the Chinese market [2][4] Company Developments - Southwest Pharmaceutical is currently the only company actively pursuing a 4th category new registration for the generic version of Atomoxetine Hydrochloride Capsules [4] - The company has increased its investment in the neuropsychiatric drug sector, with total R&D expenditure rising from 14.6 million to 28.2 million yuan from 2021 to 2024, representing an increase in revenue proportion from 1.20% to 2.28% [13][15] Market Context - The total sales of neuropsychiatric drugs in the hospital market are projected to exceed 110 billion yuan in 2024, with major market players including Renfu (21.31% market share), Shiyao Group (16.8%), and Yangtze River Pharmaceutical (approximately 13%) [4] - In 2021, the sales of Atomoxetine Hydrochloride Capsules in the full-terminal hospital market surpassed 300 million yuan, reflecting a year-on-year growth rate of 46.64% [2][4]

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on September 25, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers included: - Weikang Pharmaceutical, closing at 25.25 with a rise of 9.83% and a trading volume of 135,600 shares, totaling 329 million yuan [1] - Yisheng Pharmaceutical, closing at 7.98 with a rise of 1.53% and a trading volume of 80,000 shares, totaling 6.41 million yuan [1] - Major decliners included: - Enwei Pharmaceutical, closing at 32.25 with a drop of 3.09% and a trading volume of 8,950 shares, totaling 2.91 million yuan [2] - Zhendong Pharmaceutical, closing at 6.85 with a drop of 2.97% and a trading volume of 508,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 462 million yuan from institutional investors, while retail investors contributed a net inflow of 315 million yuan [2] - The table of capital flow indicates that: - Wanbangde had a net inflow of 23.44 million yuan from institutional investors, but a net outflow of 29.29 million yuan from retail investors [3] - Jilin Aodong experienced a net inflow of 21.10 million yuan from institutional investors, with outflows from both retail and speculative investors [3]

Core Viewpoint - Four listed companies conducted stock buybacks on September 24, with significant amounts and quantities involved [1] Group 1: Company Buyback Details - Taiji Group had the highest buyback amount, reaching 110 million yuan, with a total of 5.02 million shares repurchased [1] - Zhaoxun Media repurchased shares worth 48.18 million yuan, totaling 4.21 million shares [1] - Hunan Haili's buyback amounted to 17.43 million yuan, with 2.49 million shares repurchased [1]

Core Viewpoint - Taiji Group has completed a share buyback of 5,472,559 shares, which will be used for cancellation and reduction of registered capital, with no change in the controlling shareholder or actual controller [1][2] Summary by Sections Share Buyback Details - As of September 22, Taiji Group has repurchased 5,472,559 shares, accounting for 0.98% of the total share capital [1] - The maximum buyback price was set at 28.03 CNY per share, with a total buyback fund between 80 million CNY and 120 million CNY [1] - The actual buyback was completed at an average price of 21.92 CNY per share, totaling 120 million CNY including transaction fees, reaching the upper limit of the buyback plan [1] Impact on Shareholding Structure - After the cancellation of the repurchased shares, the combined shareholding ratio of the controlling shareholder and its concerted parties will increase from 29.82% to 30.12% without changing the controlling shareholder or actual controller [2]

Core Viewpoint - The company has successfully completed a share buyback, resulting in a change in the shareholding structure of its controlling shareholder without altering control dynamics [2][5][10]. Buyback Approval and Plan - The company approved a share buyback plan on July 16 and August 6, 2025, allowing for the repurchase of shares at a price not exceeding 28.03 CNY per share, with a total fund allocation between 80 million and 120 million CNY [3][4]. - The buyback period is set from August 6, 2025, to August 5, 2026 [3]. Buyback Implementation - As of September 22, 2025, the company repurchased 5,472,559 shares, accounting for 0.98% of the total share capital, with a total expenditure of 120 million CNY [4][5]. - The buyback was executed in accordance with the disclosed plan, and the average repurchase price was 21.92 CNY per share [4][5]. Share Cancellation Arrangement - The repurchased shares will be canceled, reducing the registered capital of the company, and the cancellation process was initiated on September 24, 2025 [9][11]. - No objections were raised by creditors during the notification period regarding the share buyback [9]. Shareholding Changes - Following the cancellation of shares, the total number of shares will decrease from 556,890,744 to 551,418,185 [10]. - The controlling shareholder's stake will increase from 29.82% to 30.12% without any change in the number of shares held, thus not affecting the control of the company [2][10].

Core Viewpoint - Tai Chi Group (600129) announced the completion of its share repurchase on September 22, 2025, having repurchased a total of 5,472,559 shares, which represents 0.98% of the company's total share capital [1] Summary by Category - **Company Actions** - The company has successfully completed a share repurchase program, acquiring 5,472,559 shares [1] - The repurchased shares account for 0.98% of the total share capital of the company [1]

证券代码：600129 证券简称：太极集团 公告编号：2025-073 重庆太极实业（集团）股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 重要内容提示： | | --- | | 回购方案首次披露日 | 2025/7/16，由董事会提议 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 日~2026 月 2025 6 8 5 | 8 | 月 | 年 | 日 | | 预计回购金额 | 8,000万元~12,000万元 | | | | | | 回购价格上限 | 28.03元/股 | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | | □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 5,472,559股 | | | | | | 实际回购股数占总股本比例 | 0.98% | | | | | | 实际回购金额 | 12,000.0 ...